Tema Oncology ETF Rating $39.26 -1.32 (-3.25%) Closing price 10/13/2026 03:59 PM EasternExtended Trading$39.27 +0.01 (+0.03%) As of 10/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.73Holdings in CANC have an aggregate rating of Moderate Buy based on 405 analyst ratings issued in the past year covering 23 companies (70.9% of the portfolio).CANC Aggregate Price Target$39.26High Prediction$39.26Average Prediction$39.26Low Prediction$39.26Holdings in CANC have an aggregate price target of $39.26 and a range of $39.26 to $39.26 covering 23 companies (70.9% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings5.25%RVMDRevolution Medicines$188.44-2.8%Moderate Buy$234.76 24.6%242.8565 of 5 stars5.22%MRKMerck & Co., Inc.$141.97-2.4%Moderate Buy$151.92 7.0%274.5776 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision4.66%LLYEli Lilly and Company$1,167.01-1.3%Moderate Buy$1,313.43 12.5%294.9233 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision4.64%COGTCogent Biosciences$28.09-5.7%Moderate Buy$51.56 83.5%122.8226 of 5 starsPositive News3.65%GMABGenmab A/S$36.57-2.1%Moderate Buy$42.50 16.2%134.1485 of 5 stars3.60%ABBVAbbVie$274.82-2.2%Moderate Buy$277.18 0.9%304.2926 of 5 starsTrending NewsAnalyst Forecast3.34%ONCBeOne Medicines$349.08-0.4%Buy$404.93 16.0%173.9918 of 5 stars3.27%EXELExelixis$59.51-0.5%Hold$50.79 -14.7%202.3312 of 5 starsAnalyst Revision3.22%HALOHalozyme Therapeutics$109.62-1.3%Moderate Buy$96.50 -12.0%123.2678 of 5 starsAnalyst Forecast3.18%BMYBristol Myers Squibb$56.73-1.5%Hold$64.88 14.4%304.7388 of 5 starsTrending NewsAnalyst Forecast3.12%IOVAIovance Biotherapeutics$14.50-0.4%Moderate Buy$13.20 -9.0%131.9259 of 5 starsAnalyst Forecast2.72%BBIOBridgeBio Pharma$63.30-3.7%Moderate Buy$105.42 66.5%243.8834 of 5 starsGap Up2.67%RHHBYRoche$53.77-0.6%Moderate Buy$60.00 11.6%123.4113 of 5 starsTrending NewsAnalyst Revision2.63%IDYAIDEAYA Biosciences$34.26-5.0%Moderate Buy$52.69 53.8%153.8687 of 5 starsPositive News2.54%IMNMImmunome$17.58-8.2%Moderate Buy$34.25 94.8%142.7722 of 5 stars2.51%CGONCG Oncology$62.40-1.2%Moderate Buy$87.50 40.2%103.6495 of 5 starsNews Coverage2.50%JNJJohnson & Johnson$248.90-5.6%Moderate Buy$276.22 11.0%254.5669 of 5 starsTrending NewsEarnings ReportDividend AnnouncementAnalyst RevisionGap DownHigh Trading Volume2.35%ELVNEnliven Therapeutics$39.49-3.3%Moderate Buy$74.44 88.5%112.7625 of 5 stars2.09%ERASErasca$14.78-4.4%Moderate Buy$22.09 49.5%112.6753 of 5 stars2.05%ZLABZai Lab$23.10-6.1%Moderate Buy$37.25 61.3%72.7813 of 5 stars1.96%RLAYRelay Therapeutics$17.36-3.4%Moderate Buy$25.92 49.3%142.4092 of 5 stars1.90%LEGNLegend Biotech$17.88+0.4%Moderate Buy$55.07 208.0%152.7172 of 5 starsAnalyst Forecast1.83%SMMTSummit Therapeutics$15.52-9.4%Moderate Buy$28.61 84.3%192.4558 of 5 starsUpcoming EarningsOptions Volume This page (NASDAQ:CANC) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
